Dynavax Technologies Corp (DVAX)

[crudeoil24]

DVAX IS A GREAT $$$$$ OPPORTUNITY > DVAX: Dynavax Reports Top Line Results of Phase 3 HEPLISAV-B(TM) Study

Both co-primary endpoints were met. The rates of clinically significant adverse events were consistent with randomization and similar to rates in prior trials and HEPLISAV-B provided a statistically significant higher rate of seroprotection than Engerix-B in diabetic participants and in all participants as a group.

Dynavax plans to resubmit the HEPLISAV-B Biologics License Application (BLA) at the end of the first quarter of 2016 and anticipates a six-month review by the FDA.

source: http://finance.yahoo.com/news/dynavax-reports-top-line-results-120000851.html